Reading POCI? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track POCI free→Reading POCI? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track POCI free→NASDAQHealth CareMedical Instruments & SuppliesSnapshot 2026-06-16
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
Recent financial performance is neutral. Earnings quality cannot be assessed since the company was unprofitable over the past year. Management's recent track record has been steady. Risk is elevated, and the sector backdrop is a headwind. Peer multiples imply a price about 82% above where it trades (it looks cheap on this basis); the read is cheap, value-trap risk. This pattern occurs because it trades below peer multiples, but recent financials are weak. The read is provisional.
Daily closes. Earnings/event dots are placed inline.
A consensus fair price across 2 valuation methods, at three horizons. Current price $5.90. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
No-growth: today's peer multiple on trailing earnings. The headline read.
Embeds projected growth. Leans optimistic by design. Upside context.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $5.90 POCI trades at 2× p/s, below its 3× p/s peer median. Our $33 fair value sits above the price; medium confidence. Not investment advice.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
The price implies about 82% below a flat-multiple fair value, below our forecast of about 48%. This describes what's priced in, not a forecast of the move.
TTM earnings are negative, so the read leans on sales- and cash-flow-based methods rather than P/E. This is a data condition, not a forward call.
No fragility gates fired. Regime (Mania) does not concentrate fragility.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated neutral grew net income 50% of the time over the next year (vs 57% for the rest of the cohort, n=3115).
Over the trailing year it converted 0.30x of net income into operating cash flow.
Not enough signal yet.
Not enough signal to read sensitivity to the US dollar, the broad stock market, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity.
5 material management or governance events in the past 24 months, led by M&A activity. Historically, Health Care names rated stable grew net income 56% of the time over the next year (vs 52% for the rest of the cohort, n=618).
The next print and the backdrop around it (sector regime and the AI cycle). Context for the path, not a forecast of returns.
EPS estimate $0.00 → $-0.06. 0 raised, 0 cut, 1 covering analysts.
0 upgrades, 0 downgrades / 30d. 100% of analysts rate Buy.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
What a normal day, a bad day, and the worst of the last year would mean for a $10,000 position.
On a typical day, $10k can swing ±$206.
How much price usually moves either way.
On a bad day, this stock has moved -$377.
A rough but not unusual down day (about the 95th percentile).
In the worst 12 months, $10k could have lost $3,434.
Deepest peak-to-trough drop in the last year.
Past results, not a forecast. Not investment advice.
The most important moves since the prior daily snapshot.
No material changes since the prior snapshot.
as of 2026-06-16
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Why it matters: Revenue growth is crucial to show the company is moving past losses. Positive growth can signal a turnaround.
Confirms:Q2 revenue growth reported above 5% year over year.
Disproves:Q2 revenue growth reported below 0% year over year.
Recent news graded against this company's own objectives — whether it reinforces or challenges the thesis, and how confirmed it is.
No graded news catalysts for POCI yet.
Conditional scenarios: if X happens, the view would shift in this direction. These are not predictions.
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
Entry into a Material Definitive Agreement. Underwriting Agreement On March 27, 2026, Precision Optics Corporation, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Lucid Capital Markets, LLC (the “Underwriter”), relating to the issuance and sale (the “Offering”) of 2,777,777 shares of its common stock, par value $0.01 per share, at a price to the public of $3.60 per share. In connection with the Offering, the Company has granted the Underwriter…
Whether the overall read has been drifting up or down lately, and how it's changed since last week.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Long-thesis check; widest uncertainty.
TTM earnings are negative. P/E-based methods drop out and the estimate leans on sales- and cash-flow-based methods. A data condition, not a forward call.
For similar setups historically (n=20,154): about 33% saw a 20%+ drawdown, and roughly 76% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
Looks cheaper than most peers in the same business.
Self-history needs ~20 months of data.
Trailing four: 2025-Q3, 2026-Q1, 2026-Q2, 2026-Q3
A side-by-side read on sector standing, valuation, and risk versus Health Care Supplies.
| Stock | Sector standing | Valuation | Risk |
|---|---|---|---|
POCI Precision Optics Corp Inc/Mass | Typical Show detailsSector percentile: 49 of 100 | inexpensive | elevated |
MDLN MEDLINE INC | — | full | moderate |
WST West Pharmaceutical Services | Above typical Show detailsSector percentile: 94 of 100 | expensive | moderate |
COO Cooper Companies (The) | Above typical Show detailsSector percentile: 75 of 100 | fair | moderate |
ALGN Align Technology | Above typical Show detailsSector percentile: 93 of 100 | fair | elevated |
Not investment advice. As of 2026-06-16.
via XLV
Tailwind = sector leading the S&P 500; headwind = trailing. Both can be constructive. Historically, headwind regimes have averaged stronger forward returns than tailwind.
Context label only: describes the market state (e.g. real bear vs narrative panic, healthy uptrend vs late-stage froth). It is not a per-ticker buy/sell signal and does not predict factor performance.
Not investment advice. As of 2026-06-16.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Focus on strategic initiatives to drive revenue growth and improve financial performance.
Stated in 3 of last 3 quarters. Revenue grew from $6,681,823 in 2026-Q1 to $8,708,631 in 2026-Q3, indicating progress in strategic initiatives. The trajectory shows delivering on revenue growth focus.
“CEO: 'We are focusing on strategic initiatives to drive revenue growth.'”
“CEO: 'Strategic initiatives are key to our revenue growth plans.'”
“CEO: 'Our strategic initiatives are aimed at increasing revenue.'”
Aim to enhance gross profit margins through operational efficiencies and cost management.
Stated in 3 of last 3 quarters. Gross profit increased from $946,358 in 2026-Q1 to $2,056,534 in 2026-Q3, showing progress in improving margins. The trajectory indicates delivering on margin improvement focus.
“CFO: 'We are working to improve our gross profit margins through efficiencies.'”
Focus on effective capital allocation to support strategic growth and financial stability.
Stated in 2 of last 2 quarters. Despite the focus on capital allocation, financials show a net income loss of $108,283 in 2026-Q3. The trajectory shows limited progress in achieving financial stability through capital allocation.
“CEO: 'Effective capital allocation is crucial for our strategic growth.'”
Why it matters: If the health care sector's growth picks up, it may help Precision Optics. A strong sector can lift all boats.
Confirms:Health care sector revenue growth reported above 12% year over year.
Disproves:Health care sector revenue growth reported below 8% year over year.
The Company issued the Representative’s Warrants pursuant to the exemption from the registration requirements of the Securities Act of 1933, as amended, available under Section 4(a)(2). 2
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. (b) and (e) On October 2, 2025, Precision Optics Corporation, Inc’s (“ POCI ” or the “ Company ”) and Mr. Mahesh Lawande mutually agreed to terminate his employment with the Company as of October 31, 2025 (the “ Termination Date ”). Effective October 1, 2025, Mr. Lawande transitioned to the roll of “Advisor to the President” for the period through…
“CFO: 'Improving gross profit margins is a key focus.'”
“CFO: 'Our goal is to enhance gross profit margins.'”
“CEO: 'We are focusing on capital allocation to support growth.'”